📰 Nasdaq Coll News
Nasdaq Coll News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Coll. Real-time updates on events, politics, business and more.
May 4, 2024
StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a strong-buy rating to a buy rating in a report published on Wednesday morning. COLL has been the subject of a number of other reports. Needham & Company LLC reiterated a buy rating and issued a $40.00 price target on shares of Collegium Pharmaceutical […]
May 2, 2024
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) will post its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect Collegium Pharmaceutical to post earnings of $1.37 per share for the quarter. Collegium Pharmaceutical has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can […]
March 29, 2024
Values First Advisors Inc. lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,865 shares of the specialty pharmaceutical company’s stock after selling 9,642 shares during the period. Values […]
March 29, 2024
Values First Advisors Inc. trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,865 shares of the specialty pharmaceutical company’s stock after selling 9,642 shares during the period. […]
March 26, 2024
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have earned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target […]
February 25, 2024
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $32.81, but opened at $34.50. Collegium Pharmaceutical shares last traded at $33.46, with a volume of 52,196 shares. Analysts Set New Price Targets Several equities research analysts have issued reports on COLL […]
February 24, 2024
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday. Several other research firms also recently commented on COLL. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $31.00 to $37.00 and gave […]
February 23, 2024
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $32.81, but opened at $34.50. Collegium Pharmaceutical shares last traded at $33.46, with a volume of 52,196 shares changing hands. Analyst Ratings Changes Several equities analysts have commented on COLL […]
February 21, 2024
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, February 22nd. Analysts expect Collegium Pharmaceutical to post earnings of $1.27 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link. Collegium […]
January 4, 2024
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its price objective increased by research analysts at Needham & Company LLC from $36.00 to $40.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price points to a potential […]